ANAPTYSBIO Business Summary

AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company that generates revenue through a high-margin licensing and financial collaboration model, primarily driven by tiered royalties and milestone payments from out-licensed therapeutic antibodies. As of February 2026, the company is executing a strategic separation into two independent, publicly traded entities: a "Royalty Management Co," anchored by substantial royalties from GSK’s Jemperli (dostarlimab) and Vanda Pharmaceuticals’ imsidolimab, and a "Biopharma Co," which focuses on a wholly-owned immunology pipeline. This pipeline is led by rosnilimab, a PD-1 agonist for rheumatoid arthritis, ANB033, a CD122 antagonist for celiac disease, and ANB101, a BDCA2 modulator. Direct competitors include Biogen, Argenx, and AbbVie; AnaptysBio distinguishes itself by leveraging its proprietary somatic hypermutation (SHM) platform to generate best-in-class antibodies while utilizing its royalty engine to provide non-dilutive capital for clinical development. The company is led by President and CEO Daniel Faga, a seasoned executive with a pedigree from Mirati Therapeutics and Spark Therapeutics, who is slated to lead the Biopharma spin-off. The executive team includes Chief Financial Officer Dennis Mulroy, formerly of La Jolla Pharmaceutical, and Chief Medical Officer Paul F. Lizzul, who previously held leadership roles at Amgen and Sienna Biopharmaceuticals. AnaptysBio was founded in 2005 with a focus on antibody engineering and has attracted a high-profile investor base, most notably Oleg Nodelman of EcoR1 Capital, who serves on the Board of Directors and represents the company’s largest shareholder. Other key board members include Independent Chairman John Orwin and Magda Marquet, with significant institutional backing from Frazier Healthcare Partners and a 2024 equity investment from Sanofi.